126937-41-5

Basic information

• Product Name: N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID
• Synonyms: 4-BOC-1-CBZ-PIPERAZINE-2-CARBOXYLIC ACID;4-N-BOC-1-N-CBZ-PIPERAZINE-2-CARBOXYLIC ACID;N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID;PIPERAZINE-1,2,4-TRICARBOXYLIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER;4-Boc-1-Cbz-2-Piperazine carboxylic acid;(±)-1-Benzyloxycarbonyl-4-Boc-piperazine-2-carboxylic acid, 97%;1-[(Benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid;Benzyloxycarbonyl-4-Boc-piperazine-2-carboxylicacid
• CAS NO: 126937-41-5
• Molecular Formula: C₁₈H₂₄N₂O₆
• Molecular Weight: 364.39
• Product Categories: Piperaizine;Piperazines
• Mol File: 126937-41-5.mol

Chemical Properties

• Melting Point: 150-152°C
• Boiling Point: 518.9 °C at 760 mmHg
• Flash Point: 267.6 °C
• Appearance: /
• Density: 1.272
• Vapor Pressure: 1.22E-11mmHg at 25°C
• Refractive Index: 1.575
• PKA: 3.68±0.20(Predicted)
• CAS DataBase Reference: N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID(126937-41-5)
• EPA Substance Registry System: N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID(126937-41-5)

Safety Data

• Hazardous Substances Data: 126937-41-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as an intermediate compound for the synthesis of various drugs, including antipsychotics and antibiotics. Its protective groups BOC and CBZ ensure the stability and reactivity of the amine groups during the synthesis process.
Used in Organic Synthesis:
In the field of organic chemistry, N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a building block for the creation of more complex molecules. Its carboxylic acid group allows for the formation of various derivatives, contributing to the development of new chemical entities.
Used in Laboratory Settings:
N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is utilized in research laboratories for the exploration of its chemical properties and potential applications. Its synthesis and reactivity are studied to understand its role in the formation of new compounds and its potential use in drug development.

Upstream product

• 501-53-1 benzyl chloroformate 
• 128019-59-0 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 2762-32-5 piperazine-2-carboxylic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1885-14-9 phenyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 98-97-5 2-pyrazylcarboxylic acid 
• 126937-42-6 piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 
• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 

Downstream Products

• 126937-42-6 piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 
• 955016-61-2 1-benzyl 4-tert-butyl 3-(aminocarbonyl)piperazine-1,4-dicarboxylate 
• 940868-18-8 1-[(benzyloxy)carbonyl]-4-(tert-butoxycarbonyl)-2-methylpiperazine-2-carboxylic acid 
• 956697-13-5 1-benzyl 4-tert-butyl 2-cyclopentyl piperazine-1,2,4-tricarboxylate 
• 955016-62-3 1-benzyl 4-(tert-butyl) 2-cyanopiperazine-1,4-dicarboxylate 
• 518048-20-9 1-benzyl-4-tert-butyl-2-cyano-2-methylpiperazine-1,4-dicarboxylate 
• 940868-24-6 1-benzyl 4-tert-butyl 2-[amino(hydroxyimino)methyl]piperazine-1,4-dicarboxylate 
• 940868-30-4 1-benzyl 4-tert-butyl 2-[amino(hydroxyimino)methyl]-2-methylpiperazine-1,4-dicarboxylate 
• 519032-03-2 2-(1,2-dimethylpiperazin-2-yl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide 
• 519032-00-9 methyl 5-(benzoyloxy)-2-[4-(tert-butoxycarbonyl)-2-methylpiperazin-2-yl]-6-hydroxypyrimidine-4-carboxylate 
• 940868-25-7 methyl 5-(benzoyloxy)-2-{1-[(benzyloxy)carbonyl]piperazin-2-yl}-6-hydroxypyrimidine-4-carboxylate 
• 940868-26-8 methyl 5-(benzoyloxy)-2-{1-[(benzyloxy)carbonyl]-4-methylpiperazin-2-yl}-6-hydroxypyrimidine-4-carboxylate 
• 519032-02-1 tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)-3,4-dimethylpiperazine-1-carboxylate 
• 519031-99-3 2-[N-(1,2-bis-methoxycarbonyl-vinyloxy)-carbamimidoyl]-2-methyl-piperazine-1,4-dicarboxylic acid 1-benzyl ester 4-tert-butyl ester 

Relevant articles and documents

TRICYCLIC PYRIDONES AND PYRIMIDONES

A compound of Formula (I) is provided: (I) where the variables are defined herein.

SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME

Disclosed are compounds, and pharmaceutically acceptable salts thereof, that can ameliorate or treat a viral infection in a subject in need thereof. The disclosure also includes conjugates of such compounds with a protease.

ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO

The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Old drug scaffold, new activity: Thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression

Thalidomide was first used for relief of morning sickness in pregnant women and then withdrawn from the market because of its dramatic effects on normal fetal development. Over the last decades, it has been used successfully for the treatment of several pathologies, including cancer. Many analogues with improved activity have been synthesized and tested. Herein we report some effects on the growth and progression of MCF-7 and MDA-MB-231 breast cancer cells by a small series of thalidomide-correlated compounds, which are very effective at inducing cancer cell death by triggering TNFα-mediated apoptosis. The most active compounds are able to drastically reduce the migration of breast cancer cells by regulation of the two major proteins involved in epithelial–mesenchymal transition (EMT): vimentin and E-cadherin. Moreover, these compounds diminish the intracellular biosynthesis of vascular endothelial growth factor (VEGF), which is primarily involved in the promotion of angiogenesis, sustaining tumor progression. The multiple features of these compounds that act on various key points of the tumorigenesis process make them good candidates for preclinical studies.

Discovery of novel N-aryl piperazine CXCR4 antagonists

A novel series of CXCR4 antagonists with substituted piperazines as benzimidazole replacements is described. These compounds showed micromolar to nanomolar potency in CXCR4-mediated functional and HIV assays, namely inhibition of X4 HIV-1IIIB virus in MAGI-CCR5/CXCR4 cells and inhibition of SDF-1 induced calcium release in Chem-1 cells. Preliminary SAR investigations led to the identification of a series of N-aryl piperazines as the most potent compounds. Results show SAR that indicates type and position of the aromatic ring, as well as type of linker and stereochemistry are significant for activity. Profiling of several lead compounds showed that one (49b) reduced susceptibility towards CYP450 and hERG, and the best overall profile when considering both SDF-1 and HIV potencies (6-20 nM).

SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

ORGANIC COMPOUNDS

Novel piperazine derivatives of the general formulae (I) and (II), with the substituent definitions as illustrated in detail in the description are described. The compounds are suitable especially as renin inhibitors and have high potency.